Baader Bank Aktiengesellschaft Sells 1,807 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Baader Bank Aktiengesellschaft trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 32.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 3,846 shares of the biopharmaceutical company’s stock after selling 1,807 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Alnylam Pharmaceuticals were worth $905,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in ALNY. Swedbank AB boosted its position in Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Swedbank AB now owns 55,532 shares of the biopharmaceutical company’s stock valued at $13,067,000 after buying an additional 1,803 shares during the period. Forsta AP Fonden lifted its stake in shares of Alnylam Pharmaceuticals by 7.7% in the 4th quarter. Forsta AP Fonden now owns 54,800 shares of the biopharmaceutical company’s stock valued at $12,895,000 after acquiring an additional 3,900 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its holdings in Alnylam Pharmaceuticals by 35.9% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 99,994 shares of the biopharmaceutical company’s stock valued at $23,530,000 after acquiring an additional 26,426 shares during the period. R Squared Ltd purchased a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $33,000. Finally, SteelPeak Wealth LLC lifted its position in Alnylam Pharmaceuticals by 40.6% in the fourth quarter. SteelPeak Wealth LLC now owns 3,480 shares of the biopharmaceutical company’s stock valued at $819,000 after purchasing an additional 1,005 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ALNY. Barclays lifted their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Bank of America upped their price objective on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a research note on Monday, October 14th. TD Cowen raised their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Finally, Sanford C. Bernstein cut their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $298.61.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $273.99 on Thursday. The business has a fifty day moving average price of $249.42 and a 200-day moving average price of $260.65. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The company has a market capitalization of $35.34 billion, a PE ratio of -104.58 and a beta of 0.34. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.15 EPS. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Insider Activity

In other news, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,416,865. The trade was a 81.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.40. The trade was a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 73,964 shares of company stock worth $20,622,925 over the last 90 days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.